Skip to main content
Premium Trial:

Request an Annual Quote

Ed Umali, David Haen, Carolyn French

Premium

A week after naming a full-time CFO, CytRx said that it has expanded its management team by three people, all of whom come from CEO Steve Kriegsman’s investment firm, The Kriegsman Group.

CytRx said that it has tapped Ed Umali as director of operations, David Haen as director of business operations, and Carolyn French as director of communications.

French’s position at CytRx is on a full-time basis, while Umali and Haen are expected to continue to provide certain services to The Kriegsman Group on a limited basis.

Following its 2002 merger with Global Genomics, CytRx was stripped down by Kriegsman and set on a new course: to develop therapeutics based on RNAi. Part of that overhaul included building a new management team, a task Kriegsman said has now completed.

“All of the slots have been filled,” he said. “We’ve got a team in place to do whatever we need to do.”

CytRx now has nine employees, he said. This does not include the roughly 10 UMass researchers conducting work for the company under a sponsored research agreement.

 

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.